AI’s Approaches to Maternal and Neonatal Health in Low Resource Settings

By Sumona Bose

December 23, 2023

Introduction

A significant challenge faced by hospitals and medical practitioners in low- and middle-income countries is the lack of sufficient healthcare facilities for timely medical diagnosis of chronic and deadly diseases. Maternal and neonatal morbidity due to non-communicable and nutrition-related diseases is a serious public health issue that leads to several deaths every year. Detecting these conditions at their early stages is challenging, putting patients at risk of developing severe conditions over time. However, the advent of Artificial Intelligence (AI) has opened up new possibilities for improving maternal and neonatal health. This article will give an overview on AI’s Approaches to Maternal and Neonatal Health in Low Resource Settings.

AI holds Promise for Maternal and Neonatal Health

AI has emerged as a practical assistive tool in various healthcare sectors, but its application in maternal and neonatal health is still in its nascent stages. One example of how AI can be used in low-resource settings is in maternal health and diagnostics services. In these settings, access to proper healthcare infrastructure and professionals is limited, making it difficult to provide holistic care to pregnant women and their children. However, AI technologies such as digital chatbots and support groups can aid in maternal and neonatal health monitoring and management. These technologies can engage users in follow-up questions about their health in their desired language, helping to disperse basic health information.

Figure 1: Focus Areas on Role of AI in complimenting maternal health

 

Challenges and Solutions for AI

Explainable Artificial Intelligence (XAI) or Dependable AI (DAI) can provide insights into the decision-making process of AI models. This level of explainability increases the confidence that medical practitioners and AI researchers have in the system, leading to broader adoption of AI in the healthcare field. By understanding why someone has been classified as ill or otherwise, the perception of AI models as a “black box” can be changed, making them more scalable and employable. XAI can be merged with smart healthcare systems that incorporate the Internet of Things, cloud computing, and AI, particularly in the fields of maternal and neonatal health. These intelligent healthcare systems can be utilized for various purposes, including disease diagnosis and treatment selection.

In some crucial small sample size healthcare problems where large datasets are not available, Few-shot learning or Zero-shot learning can be used to train AI models. These learning frameworks utilize domain information to reach medical decisions or predictions, making them efficient tools for doctors to handle rare medical conditions and problems that require years of experience.

Conclusion

Improving maternal and newborn health requires bringing speedy diagnosis and treatment to point-of-care settings in developing nations with limited resources.

Reference url

Recent Posts

Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerative Colitis Treatment

By HEOR Staff Writer

October 9, 2025

The U.S. Food and Drug Administration has granted Simponi pediatric approval for Johnson & Johnson's Simponi (golimumab), which is intended for children with moderately to severely active ulcerative colitis who weigh at least 15 kg. This historic approval is backed by data from the PURSUIT pr...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications

By João L. Carapinha

October 6, 2025

The U.S. Food and Drug Administration (FDA) has recently approved lurbinectedin SCLC therapy in combination with atezolizumab, or with atezolizumab and hyaluronidase-qvfc, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This regulatory decision reflects ...